08:46 AM EST, 12/17/2024 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Tuesday that its phase 2 trial of elraglusib with gemcitabine/nab-paclitaxel, or GnP, in metastatic pancreatic cancer met primary endpoints of one-year survival rate.

The study demonstrated a one-year survival rate of 43.6% in the elraglusib-GnP arm compared to 22.5% in the GnP control arm. Median overall survival was 9.3 months for the elraglusib combination versus 7.2 months for GnP alone, Actuate said.

Actuate said it plans to share topline data and discuss next steps, including a phase 3 registration trial, with the US Food and Drug Administration in H1 2025.